Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + irinotecan liposome-based chemotherapy ± lenvatinib for first-line treatment of advanced intrahepatic cholangiocarcinoma
ChiCTR2400089273Phase 2Not yet recruiting
- Sponsor
- Harbin Medical University Cancer Hospital
- Start
- Sep 2024
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of adebrelimab, irinotecan liposome, fluorouracil, folinic acid and lenvatinib in intrahepatic cholangiocarcinoma (ICC) (2 arms), sponsored by Harbin Medical University Cancer Hospital. Primary endpoint: Progression-free survival. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
adebrelimabirinotecan liposomefluorouracilfolinic acidlenvatinib
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on ChiCTR2400089273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400089273.